BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22002164)

  • 21. Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.
    Marty-Roix R; Vladimer GI; Pouliot K; Weng D; Buglione-Corbett R; West K; MacMicking JD; Chee JD; Wang S; Lu S; Lien E
    J Biol Chem; 2016 Jan; 291(3):1123-36. PubMed ID: 26555265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses.
    Fox CB; Moutaftsi M; Vergara J; Desbien AL; Nana GI; Vedvick TS; Coler RN; Reed SG
    Vaccine; 2013 Dec; 31(49):5848-55. PubMed ID: 24120675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery.
    Gregg KA; Harberts E; Gardner FM; Pelletier MR; Cayatte C; Yu L; McCarthy MP; Marshall JD; Ernst RK
    mBio; 2017 May; 8(3):. PubMed ID: 28487429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist.
    Jung ID; Jeong SK; Lee CM; Noh KT; Heo DR; Shin YK; Yun CH; Koh WJ; Akira S; Whang J; Kim HJ; Park WS; Shin SJ; Park YM
    Cancer Res; 2011 Apr; 71(8):2858-70. PubMed ID: 21368092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen.
    McKay PF; Cope AV; Mann JF; Joseph S; Esteban M; Tatoud R; Carter D; Reed SG; Weber J; Shattock RJ
    PLoS One; 2014; 9(1):e84707. PubMed ID: 24465426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.
    Arias MA; Van Roey GA; Tregoning JS; Moutaftsi M; Coler RN; Windish HP; Reed SG; Carter D; Shattock RJ
    PLoS One; 2012; 7(7):e41144. PubMed ID: 22829921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells.
    Schneider LP; Schoonderwoerd AJ; Moutaftsi M; Howard RF; Reed SG; de Jong EC; Teunissen MB
    Vaccine; 2012 Jun; 30(28):4216-24. PubMed ID: 22542815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice.
    Zhou J; Cheung AK; Tan Z; Wang H; Yu W; Du Y; Kang Y; Lu X; Liu L; Yuen KY; Chen Z
    J Clin Invest; 2013 Jun; 123(6):2629-42. PubMed ID: 23635778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector.
    Lebedeva E; Bagaev A; Pichugin A; Chulkina M; Lysenko A; Tutykhina I; Shmarov M; Logunov D; Naroditsky B; Ataullakhanov R
    BMC Immunol; 2018 Jul; 19(1):26. PubMed ID: 30055563
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Zhang W; Ahmad G; Molehin AJ; Torben W; Le L; Kim E; Lazarus S; Siddiqui AJ; Carter D; Siddiqui AA
    J Investig Med; 2018 Dec; 66(8):1124-1132. PubMed ID: 29997146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.
    Tada H; Aiba S; Shibata K; Ohteki T; Takada H
    Infect Immun; 2005 Dec; 73(12):7967-76. PubMed ID: 16299289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo targeting of protein antigens to dendritic cells using anti-DEC-205 single chain antibody improves HIV Gag specific CD4
    Ngu LN; Nji NN; Ambada GE; Sagnia B; Sake CN; Tchadji JC; Njambe Priso GD; Lissom A; Tchouangueu TF; Manga Tebit D; Waffo AB; Park CG; Steinman RM; Überla K; Nchinda GW
    Immun Inflamm Dis; 2019 Jun; 7(2):55-67. PubMed ID: 28474788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.
    Coler RN; Bertholet S; Moutaftsi M; Guderian JA; Windish HP; Baldwin SL; Laughlin EM; Duthie MS; Fox CB; Carter D; Friede M; Vedvick TS; Reed SG
    PLoS One; 2011 Jan; 6(1):e16333. PubMed ID: 21298114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates.
    Flynn BJ; Kastenmüller K; Wille-Reece U; Tomaras GD; Alam M; Lindsay RW; Salazar AM; Perdiguero B; Gomez CE; Wagner R; Esteban M; Park CG; Trumpfheller C; Keler T; Pantaleo G; Steinman RM; Seder R
    Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7131-6. PubMed ID: 21467219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toll-Like Receptor 4 Regulates Rabies Virus-Induced Humoral Immunity through Recruitment of Conventional Type 2 Dendritic Cells to Lymph Organs.
    Chen C; Zhang C; Li H; Wang Z; Yuan Y; Zhou M; Fu ZF; Zhao L
    J Virol; 2021 Nov; 95(24):e0082921. PubMed ID: 34613801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
    Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
    Front Immunol; 2021; 12():786144. PubMed ID: 35095862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
    Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
    J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine.
    Park HJ; Jang GY; Kim YS; Park JH; Lee SE; Vo MC; Lee JJ; Han HD; Jung ID; Kang TH; Park YM
    J Immunother Cancer; 2019 Feb; 7(1):60. PubMed ID: 30819254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.